Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MDMA
Biotech
Transcend links MDMA analog to PTSD improvements in phase 2
Transcend linked its MDMA analog to improvements in PTSD symptoms that began on Day 8 and persisted through Day 64 of its phase 2 trial.
Nick Paul Taylor
Mar 31, 2025 8:00am
Lykos still plotting path to approval for rejected MDMA therapy
Jan 17, 2025 9:00am
Lykos accepts FDA view that MDMA med needs new trial for approval
Oct 21, 2024 8:31am
After FDA rejection and layoffs, Lykos' CEO is leaving
Sep 5, 2024 1:39pm
PharmAla launches tool aimed at easing access to MDMA drug info
Aug 28, 2024 12:55pm
Lykos caps off chaotic week by cutting 75% of staff
Aug 15, 2024 3:59pm